Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute

Mayo Clinic Proceedings

Volumn 72, Issue 10, 1997, Pages 901-912

  Chute, John P ^a   Venzon, David J ^b   Hankins, Lynn ^c   Okunieff, Paul ^d   Frame, James N ^e   Ihde, Daniel C ^f   Johnson, Bruce E ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Biostatistics and Data Management Section   (United States)

^c Vascular Medicine Branch   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0030770953     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)63359-4     Document Type: Article

References (51)

1. Mountain CF. Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol 1978; 5:272-279
2. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: ten-year follow-up. Lancet 1973;2:63-65
3. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46:516-525
4. Bergsagel DE, Jenkin RD, Pringle JF, White DM, Fetterly JC, Klaassen DJ, et al. Lung cancer: clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 1972;30:621-627
5. Petrovich Z, Ohanian M, Cox J. Clinical research on the treatment of locally advanced lung cancer: final report of VALG Protocol 13 Limited. Cancer 1978;42:1129-1134
6. Medical Research Council Lung Cancer Working Party. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 1979;40:110
7. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-1441
8. Aisner J. Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 1996; 14: 658-665
9. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12:2022-2034
10. Johnson DH, Wolff SN, Hainsworth JD, Porter LL, Grosh WW, Hande KR, et al. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 1985;3:170-175
11. Cohen MH, Ihde DC, Bunn PA Jr, Fossieck BE Jr, Matthews MJ, Shackney SE, et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 1979;63:163-170
12. Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada [published erratum appears in Ann Intern Med 1988;108:496]. Ann Intern Med 1987; 107:451-458
13. Brower M, Ihde DC, Johnston-Early A, Bunn PA Jr, Cohen MH, Carney DN, et al. Treatment of extensive stage small cell bronchogenic carcinoma: effects of variation in intensity of induction chemotherapy. Am J Med 1983;75:993-1000
14. Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991:9:1632-1638
15. Ihde DC, Deisseroth AB, Lichter AS, Bunn PA, Carney DN, Cohen MH, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 1986; 4:1443-1454
16. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected smallcell carcinoma of the lung: a randomized study. J Clin Oncol 1987;5:1864-1873
17. Bunn PA Jr, Lichter AS, Makuch RW, Cohen MH, Veach SR, Matthews MJ, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987; 106:655-662
18. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-918
19. Pignon J-P, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327: 1618-1624
20. Johnson BE, Ihde DC, Bunn PA, Becker B, Walsh T, Weinstein ZR, et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation: data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 1985:103:430-438
21. Johnson BE, Ihde DC, Matthews MJ, Bunn PA, Zabell A, Makuch R W, et al. Non-small-cell lung cancer: major cause of late mortality in patients with small cell lung cancer. Am J Med 1986;80:1103-1110
22. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-1295
23. Clarkson B, Berman E, Little C, Andreeff M, Kempin S, Kolitz J, et al. Update on clinical trials of chemotherapy and bone marrow transplantation in acute myelogenous leukemia in adults at Memorial Sloan-Kettering Cancer Center (MSKCC) 1966 to 1989. In: Gale RP, editor. Acute Myelogenous Leukemia: Progress and Controversies. New York: Wiley-Liss; 1990. pp 239-272
24. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-1781
25. Turrisi AT III. Innovations in multimodality therapy for lung cancer: combined modality management of limited small-cell lung cancer. Chest 1993;103(Suppl):56S59S
26. Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF, et al. Histopathologic classification of small cell lung cancer: changing concepts and terminology. Cancer 1988;62:973-977
27. Linnoila RI, Aisner SC. Pathology of lung cancer: an exercise in classification. In: Johnson BE, Johnson DH, editors. Lung Cancer. New York: Wiley-Liss; 1995. pp 73-95
28. Dearing MP, Steinberg SM, Phelps R, Anderson MJ, Mulshine JL, Ihde DC, et al. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 1990;8:1042-1049
29. Catane R, Lichter A, Lee YJ, Brereton HD, Schwade JG, Glatstein E. Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer 1981; 48:1936-1943
30. Cohen MH, Creaven PJ, Fossieck BE Jr, Broder LE, Selawry OS, Johnston AV, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977;61: 349-354
31. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14:806813
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAmStatAssoc 1958;53:457-481
33. Cox DR. Regression models and life-tables [with discussion]. JRStatSoc[B] 1972;34:187-220
34. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574
35. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research [published erratum appears in Br J Cancer 1990;62:550]. Br J Cancer 1990;61:597-604
36. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344-354
37. Johnson BE, Steinberg SM, Phelps R, Edison M, Veach SR, Ihde DC. Female patients with small cell lung cancer live longer than male patients. AmJMed 1988;85:194-196
38. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer: expanded Southwest Oncology Group experience. Chest 1991;99:1425-1432
39. Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 1992;84:1077-1084
40. Rowinsky EK, Ettinger DS. Drug development and new drugs for lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung Cancer: Principles and Practice. Philadelphia: Lippincott-Raven; 1996. pp 793-810
41. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890895
42. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861
43. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291
44. Turrisi AT III, Glover DJ, Mason BA. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiât Oncol Biol Phys 1988;15:183-187
45. Turrisi AT III, Glover DJ. Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. Int J Radiât Oncol Biol Phys 1990; 19: 1473-1479
46. Johnson DH, Turrisi AT, Chang AY, Blum R, Bonomi P, Ettinger D, et al. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:879-884
47. Turrisi A, Wagner H, Glover D, Mason B, Oken M, Bonomi P (Eastern Cooperative Oncology Group [ECOG]). Limited small cell lung cancer (LSCLC): concurrent BID thoracic radiotherapy (TRT) with platinum-etoposide (PE); an ECOG study [abstract]. Program Proc Am Soc Clin Oncol 1990; 9:230
48. Johnson DH, Kirn K, Turrisi AT, Sause W, Komaki R, Wagner H, et al. Cisplatin (P) & etoposide (E) + concurrent thoracic radiotherapy (TRT) administered once versus twice daily for limited-stage (LS) small cell lung cancer (SCLC): preliminary results of an intergroup trial [abstract]. Program Proc Am Soc Clin Oncol 1994;13:333
49. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-607
50. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al (National Cancer Institute of Canada Clinical Trials Group). Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336-344
51. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N EnglJMed 1985;312:1604-1608